Here's a novel solution. Big pharma companies partner with smaller biotech companies that have promising new drug or methodological improvements. Big pharma can spend less on R&D, and improve the chances that they have those blockbusters. In the end, the consumers pay less, and the cost controls most countries have enacted (in part due to the failing model in large phamaceuticals operations) will have much less impact on pricing in the US.